NovaBridge Biosciences (NBP)
1.02
-0.05
(-4.67%)
USD |
NASDAQ |
Nov 03, 14:20
NovaBridge Biosciences Total Liabilities (Quarterly) : 29.58M for Dec. 31, 2025
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2025 | 29.58M |
| September 30, 2025 | 18.50M |
| June 30, 2025 | 9.975M |
| March 31, 2025 | 10.60M |
| December 31, 2020 | 108.05M |
| Date | Value |
|---|---|
| September 30, 2020 | 81.03M |
| December 31, 2019 | 540.99M |
| September 30, 2019 | 76.45M |
| December 31, 2018 | 484.81M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Xencor, Inc. | 221.73M |
| Arrivent BioPharma, Inc. | 27.88M |
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.391B |
| Anika Therapeutics, Inc. | 46.19M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 260.52M |
| Shareholders Equity (Quarterly) | 230.94M |